Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-06-26
1999-07-27
Ketter, James
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
435325, 536 231, C12N 1566
Patent
active
059290439
ABSTRACT:
Nucleoproteins comprising overlapping homologous DNA sequences coated with a recombinase are employed for introduction into cells to produce double D-loop structures. The sequences may be modified with various moieties which result in modification of DNA. Formation of the D-loops results in inhibition of replication and transcription, where the moieties can be employed for permanent scission or modification of the DNA. The methods and compositions can be used for investigating physiological processes, for producing animal models, and for inhibition of an undesirable phenotype in vivo.
REFERENCES:
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5273881 (1993-12-01), Sena et al.
Revet, et al., Homologous DNA Targeting with RecA Protein-Coated Short DNA Probes and Electron Microscope Mappingon Linear Duplex Molecules (1993) Reprinted from J. Mol. Biol. 232:779-791.
Sena, et al., Targeting in Linear DNA Duplexes with Two Complementary Probe Strands for Hybrid Stability (Apr. 1993) Nature Genetics, pp. 365-372.
Ketter James
Pangene Corporation
Silva, Esq. Robin M.
Trecartin, Esq. Richard F.
LandOfFree
Recombinase mediated DNA therapies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinase mediated DNA therapies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinase mediated DNA therapies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-878795